Nicolas Barry Delongchamps

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/396250/publications.pdf

Version: 2024-02-01

30 papers 1,618 citations

759233 12 h-index 27 g-index

30 all docs 30 docs citations

times ranked

30

2316 citing authors

#	Article	IF	CITATIONS
1	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology, The, 2019, 20, 100-109.	10.7	701
2	Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2â€weighted, dynamic contrastâ€enhanced and diffusionâ€weighted imaging. BJU International, 2011, 107, 1411-1418.	2.5	278
3	Prebiopsy Magnetic Resonance Imaging and Prostate Cancer Detection: Comparison of Random and Targeted Biopsies. Journal of Urology, 2013, 189, 493-499.	0.4	248
4	Detection of Significant Prostate Cancer with Magnetic Resonance Targeted Biopsies—Should Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Biopsies Alone be a Standard of Care?. Journal of Urology, 2015, 193, 1198-1204.	0.4	76
5	Outcome of Patients with Fortuitous Prostate Cancer after Radical Cystoprostatectomy for Bladder Cancer. European Urology, 2005, 48, 946-950.	1.9	38
6	Are Magnetic Resonance Imaging-Transrectal Ultrasound GuidedÂTargeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?. Journal of Urology, 2016, 196, 1069-1075.	0.4	37
7	Role of vascular endothelial growth factor in prostate cancer. Urology, 2006, 68, 244-248.	1.0	36
8	Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsiesâ€"Are We Gaining in Accuracy?. Journal of Urology, 2016, 195, 88-93.	0.4	35
9	Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?. European Urology Focus, 2018, 4, 760-767.	3.1	26
10	Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology, 2017, 35, 229-235.	2.2	25
11	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. Oncolmmunology, 2017, 6, e1358330.	4.6	15
12	Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 65-71.	2.2	14
13	High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncology Letters, 2016, 11, 1375-1381.	1.8	11
14	PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	1.8	10
15	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Scientific Reports, 2020, 10, 16641.	3.3	10
16	Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. International Urology and Nephrology, 2021, 53, 1757-1763.	1.4	10
17	Microcalcifications, calcium-sensing receptor, and cancer. Cell Calcium, 2019, 82, 102051.	2.4	8
18	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS ONE, 2021, 16, e0252040.	2.5	8

#	Article	IF	CITATIONS
19	Re: Role of Magnetic Resonance Imaging Before Initial Biopsy: Comparison of Magnetic Resonance Imaging–Targeted and Systematic Biopsy for Significant Prostate Cancer Detection. European Urology, 2012, 61, 622-623.	1.9	5
20	Re: Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. European Urology, 2012, 62, 350-351.	1.9	5
21	Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. World Journal of Urology, 2018, 36, 921-929.	2.2	5
22	Giant Primary Scrotal Lipoma: A Rare Entity with Diagnostic Pitfalls. Case Reports in Urology, 2020, 2020, 1-3.	0.3	5
23	Perspectives on the urological care in Parkinson's disease patients. Archivio Italiano Di Urologia Andrologia, 2022, 94, 107-117.	0.8	4
24	Prospective comparison of scar-related satisfaction and quality of life after laparoscopic versus open radical prostatectomy: no differences from patients' point of view. World Journal of Urology, 2013, 31, 389-393.	2.2	3
25	Unstable angina following intracavernous injection of alprostadil: a case study. BMJ Case Reports, 2009, 2009, bcr0320091658-bcr0320091658.	0.5	2
26	Integrated US-MR fusion images and MR targeted biopsies. What are their role and value in the detection and follow-up of prostate cancer. Archivos Espanoles De Urologia, 2015, 68, 349-53.	0.2	2
27	TMPRSS2–ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material. World Journal of Urology, 2015, 33, 807-811.	2.2	1
28	Identification of a prognostic molecular signature composed of 3 genes involved in immunity in muscle-invasive bladder cancer Journal of Clinical Oncology, 2017, 35, e16029-e16029.	1.6	0
29	A Challenging Case of Ureteroiliac Artery Fistula Managed With an Endovascular Approach. Vascular and Endovascular Surgery, 0, , 153857442211058.	0.7	O
30	Comparison of oncological, surgical, and functional outcomes between radical retropubic and radical perineal prostatectomy: A multi-institutional study. Urologia, 0, , 039156032211112.	0.7	0